SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc is seeing intense community debate as retail investors push for a short squeeze amid high short interest and technical breakouts, while skeptics point to recycled narratives regarding potential competition. The stock continues to draw significant options volume and retail attention as traders track its momentum against historical resistance levels.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is experiencing an intense, parabolic short squeeze driven by extreme ownership concentration among a few hedge funds that have effectively locked up the available float. Community sentiment is deeply divided, with many traders debating the mechanics of the squeeze versus the company's weak underlying fundamentals, leading to high-stakes discussion on whether to chase the momentum or prepare for an inevitable, sharp correction.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying as investors react to CFO Thomas Mika's recent interview, where he directly countered short-seller reports and signaled that the company expects purchase orders far exceeding previous levels. The community is heavily focused on the companys scaling manufacturing capacity to support hyperscale data center demand, leading to significant retail enthusiasm and speculation regarding a potential short squeeze.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple (XRP) is trending as investors debate its decoupling from Bitcoin and track its potential role in institutional DeFi, with significant community focus on the impact of the CLARITY Act. While some holders express frustration over stagnant price action and compare it to broader market trends, others remain optimistic about long-term institutional adoption and ongoing ledger activity.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor (NVTS) is surging on massive volume as investor conviction grows regarding its GaN and SiC technology, which is viewed as essential for the next generation of AI data centers. While the community is divided between bullish anticipation of potential partnerships and design wins, others are actively debating high short interest and fundamental valuation concerns.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is seeing intense investor activity driven by a strategic board overhaul, anticipation of major regulatory de-risking catalysts, and high-conviction institutional accumulation. The community is focused on the company's long-term potential as a critical power provider for AI data centers, while actively monitoring short-interest data and the upcoming criticality milestone for its Aurora reactor.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is seeing increased investor optimism driven by speculation that Dr. Houman Hemmati, a former company executive with experience in exosome and cell therapy development, is a leading candidate to head the FDA's CBER. Community discourse is highly bullish, with many investors anticipating that a new leadership appointment and the upcoming PDUFA date for deramiocel will serve as major catalysts for a potential breakthrough.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon (GRPN) is experiencing intense social media activity as traders speculate on its potential for a short squeeze, driven by a tight float and high short interest. Community discussions are split between those betting on a parabolic run due to institutional accumulation and skeptical investors who view the current price action as manipulated and disconnected from the company's long-term business fundamentals.

Chip

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IBRX
If you have CIS + Papillary tumors (the flat cancer plus the finger-like growths), you are fully covered under the new EU authorization.
If you have Papillary-only disease (meaning no CIS is present in your pathology report), it is not technically part of the &quot;on-label&quot; indication in Europe yet.
2026 NCCN Update Matters for Europe
formal EU label mirrors the FDA&#39;s &quot;CIS-centric&quot; language, the NCCN v1.2026 updates we discussed are being used by European oncologists to bridge this gap:
European doctors often look to NCCN guidelines as the global &quot;gold standard.&quot; Since the NCCN now explicitly links CIS and papillary disease (the &quot;clonal link&quot;), a doctor in the EU can use this evidence to justify prescribing it for a papillary-only patient.
The 2026 guidelines highlight the 96% survival rate for the papillary-only cohort (Cohort B), which gives European patients a strong &quot;Right to Treat&quot; argument when negotiating with national health systems like Germany&#39;s G-BA or France&#39;s HAS.

Johann

NTyoda

Ricardo Sande

Wayne

Rich rellihen

Paul

JLH1903

zaltenbairt

Elizabeth Brown

Jon brand

StockTwits for iOS

ImmunityBio Inc


If you have CIS + Papillary tumors (the flat cancer plus the finger-like growths), you are fully covered under the new EU authorization.
If you have Papillary-only disease (meaning no CIS is present in your pathology report), it is not technically part of the "on-label" indication in Europe yet.
2026 NCCN Update Matters for Europe
formal EU label mirrors the FDA's "CIS-centric" language, the NCCN v1.2026 updates we discussed are being used by European oncologists to bridge this gap:
European doctors often look to NCCN guidelines as the global "gold standard." Since the NCCN now explicitly links CIS and papillary disease (the "clonal link"), a doctor in the EU can use this evidence to justify prescribing it for a papillary-only patient.
The 2026 guidelines highlight the 96% survival rate for the papillary-only cohort (Cohort B), which gives European patients a strong "Right to Treat" argument when negotiating with national health systems like Germany's G-BA or France's HAS.